Lerner U H, Larsson A
Bone. 1987;8(3):179-89. doi: 10.1016/8756-3282(87)90018-4.
The effects of 3-amino-1-hydroxy-propylidene-1,1-bisphosphonate (AHPrBP), 1-hydroxyethylidene-1,1-bisphosphonate (HEBP), dichloromethylenebisphosphonate (Cl2MBP) and azacycloheptylidene-2,2-bisphosphonate (AHBP) on bone were examined in organ culture using newborn mice calvaria. AHPrBP, HEBP and Cl2MBP caused a dose-dependent inhibition of PTH-stimulated (10 nmol/l) release of 45Ca from the calvaria, at and above a concentration of 3 mumol/l, whereas AHBP only caused a slight inhibition, at and above 100 mumol/l. AHPrBP inhibited PTH-stimulated release of 3H from bones prelabelled with [3H]-proline. AHPrBP (30 mumol/l) diminished the stimulatory effect of 1 alpha(OH)vitamin D3 (10 nmol/l), prostaglandin E2 (0.1 mumol/l) and renal tumor conditioned media on 45Ca release. AHPrBP and Cl2MBP, at and above 3 mumol/l, decreased PTH-stimulated mobilization of Ca2+ and Pi and in parallel the release of beta-glucuronidase without affecting the release of lactate dehydrogenase. The inhibitory effect of AHPrBP (30 mumol/l) on PTH-induced 45Ca release was irreversible. The inhibition by AHPrBP (30 mumol/l) on spontaneous and PTH-stimulated release of 45Ca can be seen first after 24 h of culture. Similarly the inhibitory effect by HEBP (30 mumol/l) and Cl2MBP (30 mumol/l) was delayed and could be observed after 36 and 24 h of culture, respectively. PTH-stimulated release of Ca2+, Pi, beta-glucuronidase and beta-N-acetylglucosaminidase was reduced by AHPrBP first after 24 h of culture. AHPrBP, HEBP and Cl2MBP, at concentrations which are inhibitory on bone resorption, do not affect protein synthesis and mitotic activities in mouse calvaria. These data show that AHPrBP, HEBP and Cl2MBP inhibit bone resorption in vitro and in parallel decrease lysosomal enzyme release by a mechanism, which is not related to cytotoxicity. In addition, the delayed inhibitory effect on bone resorption and lysosomal enzyme release by all the compounds suggest that bisphosphonates inhibit bone resorption indirectly and not by a direct effect on existing osteoclasts. The delayed inhibition by bisphosphonates on bone resorption may be due to decreased recruitment of new osteoclasts as a consequence of an inhibitory action on mononuclear osteoclast precursor cells.
利用新生小鼠颅骨进行器官培养,研究了3-氨基-1-羟基亚丙基-1,1-二膦酸酯(AHPrBP)、1-羟基亚乙基-1,1-二膦酸酯(HEBP)、二氯亚甲基双膦酸酯(Cl2MBP)和氮杂环庚亚基-2,2-二膦酸酯(AHBP)对骨骼的影响。AHPrBP、HEBP和Cl2MBP在浓度为3 μmol/l及以上时,对甲状旁腺激素(PTH)刺激(10 nmol/l)的颅骨45Ca释放产生剂量依赖性抑制,而AHBP仅在100 μmol/l及以上时产生轻微抑制。AHPrBP抑制了用[3H]-脯氨酸预标记的骨骼中PTH刺激的3H释放。AHPrBP(30 μmol/l)减弱了1α(OH)维生素D3(10 nmol/l)、前列腺素E2(0.1 μmol/l)和肾肿瘤条件培养基对45Ca释放的刺激作用。AHPrBP和Cl2MBP在浓度为3 μmol/l及以上时,降低了PTH刺激的Ca2+和Pi动员,并同时降低了β-葡萄糖醛酸酶的释放,而不影响乳酸脱氢酶的释放。AHPrBP(30 μmol/l)对PTH诱导的45Ca释放的抑制作用是不可逆的。AHPrBP(30 μmol/l)对45Ca自发和PTH刺激释放的抑制作用在培养24小时后才首次出现。同样,HEBP(30 μmol/l)和Cl2MBP(30 μmol/l)的抑制作用也有延迟,分别在培养36小时和24小时后可观察到。培养24小时后,AHPrBP首先降低了PTH刺激的Ca2+、Pi、β-葡萄糖醛酸酶和β-N-乙酰氨基葡萄糖苷酶的释放。AHPrBP、HEBP和Cl2MBP在对骨吸收有抑制作用的浓度下,不影响小鼠颅骨中的蛋白质合成和有丝分裂活性。这些数据表明,AHPrBP、HEBP和Cl2MBP在体外抑制骨吸收,并同时通过一种与细胞毒性无关的机制降低溶酶体酶的释放。此外,所有化合物对骨吸收和溶酶体酶释放的延迟抑制作用表明双膦酸盐间接抑制骨吸收,而不是对现有破骨细胞有直接作用。双膦酸盐对骨吸收的延迟抑制可能是由于对单核破骨细胞前体细胞的抑制作用导致新破骨细胞招募减少。